Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June
June 15, 2023 06:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
May 25, 2023 06:00 ET
|
Reviva Pharmaceuticals
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function,...
Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
May 22, 2023 06:30 ET
|
Reviva Pharmaceuticals
Data reinforce brilaroxazine’s differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion...
Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform
May 19, 2023 06:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023
May 18, 2023 06:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 15, 2023 16:05 ET
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated...
Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
May 12, 2023 06:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data
May 11, 2023 06:30 ET
|
Reviva Pharmaceuticals
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel...
Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023
May 04, 2023 06:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives
May 01, 2023 16:01 ET
|
Reviva Pharmaceuticals
Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical...